Press Releases Keyword Search Year None20262025202420232022202120202019201820172016201520142013 June 23, 2020 Editas Medicine Announces Offering of Common Stock June 12, 2020 Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease May 15, 2020 Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies May 7, 2020 Editas Medicine Announces First Quarter 2020 Results and Update April 30, 2020 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update April 29, 2020 Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers March 4, 2020 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 February 26, 2020 Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update February 19, 2020 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update January 13, 2020 Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last »
June 12, 2020 Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
May 15, 2020 Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies
April 30, 2020 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
April 29, 2020 Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
March 4, 2020 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
February 19, 2020 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update
